The uncertainty surrounding changes at the FDA and other market dynamics is reshaping the global drug development landscape. In this webinar, CRO regulatory leaders will summarize the collective experience of the biotech companies we’ve spoken to recently. We will explore:

• The impact of the FDA leadership changes, staffing cuts, and return to office mandates in reshaping regulatory priorities.

• Trends we’re observing from biotech sponsors on the decision of whether or not to keep trials in the US.

• The broader implications for industry investment, pipeline prioritization strategies, and international responses.

This episode is part 1 of 4 in the series “Navigating Regulatory Changes & Market Dynamics: CRO Perspectives on the Future of Clinical Trials”, featuring insights from Novotech on evolving trends impacting global clinical development. Stay tuned for the next episode, where we’ll continue exploring the key forces shaping the future of clinical trials.